New EU Action Plan To Boost Innovation By Smaller Firms
Executive Summary
A new action plan from the European Medicines Agency is intended to promote innovation in SMEs by raising awareness of the regulatory tools and support available from the agency, offering more training and education, and promoting collaboration among SMEs, academia, and other stakeholders.
You may also be interested in...
SMEs Making The Most Of EU Centralized Procedure And Scientific Support From EMA
Smaller biopharmaceutical firms are increasingly making use of the EU’s centralized approvals procedure and the EMA’s scientific advice and other support services, and are also proving to be keen users of the agency’s priority medicines scheme (PRIME), accounting for half of all PRIME applications in 2016.
EMA Tightens Links With Academia To Boost Innovation And Regulatory Science
A new framework for interactions between the EMA and the academic community is expected to foster innovation in new drugs and evaluation methodologies, by keeping the agency in touch with cutting-edge research and giving academics the chance to benefit more from the expertise in the EU regulatory network.
Keeping Track Of IDMP Moves In The EU, US And Beyond
Ian Schofield reports on how regulatory agencies are faring with regard to adopting five ISO standards for the identification of medicinal products.